Search Results

The Sonata® Transcervical Fibroid Ablation System 2.2 is intended for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids, including those associated with heavy menstrual bleeding.

The Sonata System 2.2 provides radiofrequency (RF) ablation of uterine fibroids using a transcervical approach that is uterine sparing without incisions or material uterine distension. The system enables a clinician to deliver radiofrequency energy to fibroid tissue resulting in thermal fixation and coagulative necrosis of the tissue.

The system combines two technologies - ultrasound for visualization, and radiofrequency energy for ablative therapy - in a single integrated handpiece.

The Sonata System is comprised of medical equipment, software, and various single-use and reusable instruments. The change associated with this submission regards a change to materials, labeling artwork, and cable length of the Sonata Dispersive Electrode.

A single-use Radiofrequency Ablation (RFA) Handpiece attaches to a reusable Intrauterine Ultrasound (IUUS) Probe to provide sonography-guided RF ablation. Once connected, the combination is referred to as the "Treatment Device". The RFA Handpiece connects to the Sonata RF Generator and contains the Needle Electrodes that deliver radiofrequency energy to the target tissue. Dispersive Electrodes are placed on the patient's thighs and connected to the RF Generator to complete the electrical circuit. The IUUS Probe connects to the SMART Tablet and provides diagnostic ultrasound imaging and guidance. Ultrasound guidance is used to localize the fibroids from within the uterine cavity, guide placement of the RFA Handpiece Needle Electrodes into a target fibroid and ensure safety with respect to the serosa. When the Needle Electrodes are anchored within tissue, the physician is able to pivot the IUUS Probe transducer around the Needle Electrodes in order to confirm safety of the uterine serosa through multiple ultrasound planes.

The Sonata System allows for treatment planning through the use of a graphical interface and automated control of RF energy delivery.

Sonata Graphical Guidance Software (GGS) includes the SMART Guide and integrates treatment planning, targeting, and ablation of fibroids. The SMART Guide displays a real-time graphic overlay on the live ultrasound image for targeting and deployment of radiofrequency ablation.

Two main elements of the SMART Guide are the Ablation Zone and the Thermal Safety Border.

• Ablation Zone (red inner ellipse) – a two-dimensional representation of the outer boundary of the average region of tissue ablation for the selected ablation size
• Thermal Safety Border (green outer ellipse) – the distance at which tissue outside of the Ablation Zone is safe from the potential of thermal damage.

The provided text is an FDA 510(k) clearance letter for the Gynesonics Sonata® Transcervical Fibroid Ablation System 2.2. It details the device's indications for use, technological comparison to a predicate device, and a summary of non-clinical and/or clinical tests performed.

Crucially, this document states that the changes made to the device (materials, labeling artwork, and cable length of the Dispersive Electrode) were minor and did not raise new questions of safety and effectiveness. For such minor modifications, the FDA typically does not require extensive new clinical studies comparing the modified device's performance against detailed acceptance criteria in the manner of an AI/ML algorithm. Instead, the focus is on demonstrating that the modified device still meets existing design requirements and is as safe and effective as its predicate.

Therefore, the information required to answer most of your specific questions regarding acceptance criteria and a study proving the device meets them (especially in the context of an AI/ML algorithm with detailed performance metrics) is not present in this regulatory document. The document describes a modification to an existing, already cleared device, not an initial clearance that would require a new, comprehensive clinical study with detailed performance outcomes.

The "study that proves the device meets the acceptance criteria" in this context refers to the verification and validation testing of the modified components to ensure they still meet the established safety and performance characteristics of the original cleared device. This is primarily non-clinical testing.

Here's how to address your points based on the provided text:

Acceptance Criteria and Device Performance

As this document describes a modification to an already cleared device, not a new device requiring novel clinical performance acceptance criteria, the detailed table you requested is not explicitly provided in the text. The acceptance criteria referenced are for the modified components to ensure they don't negatively impact the established safety and effectiveness of the predicate device.

Note: The document states, "In all cases, the verification and validation testing met acceptance criteria with and without justification." This implies that the tests confirmed the modified components did not degrade the performance or safety of the system, aligning with the predicate device's established levels.

2. Sample Size Used for the Test Set and Data Provenance

• Sample Size: The document does not specify a "test set" sample size in terms of patient data for a clinical study. The testing described (biocompatibility, mechanical performance, etc.) refers to non-clinical, in-vitro, or bench testing of the modified device components.
• Data Provenance: Not applicable as this is primarily non-clinical testing of device components, not a clinical study on patient populations with geographical data provenance.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications

• This is not applicable to the type of testing described in the document. Ground truth establishment by experts (e.g., radiologists for imaging studies) is relevant for clinical studies, particularly those involving AI/ML algorithms, which is not the primary focus of this 510(k) for a device modification. The "ground truth" here is the established safety and performance of the predicate device, against which the modified device's components were evaluated.

4. Adjudication Method for the Test Set

• Not applicable for the non-clinical component testing described.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done, and the Effect Size of Human Reader Improvement with AI vs. Without AI Assistance

• Not applicable. This device is a surgical ablation system, not an AI/ML diagnostic or assistive imaging tool that would undergo MRMC studies. The document describes a physical medical device and its modifications.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was done

• Not applicable. This is a physical medical device. While it has "Graphical Guidance Software (GGS)" with "SMART Guide," the focus of this 510(k) is a modification to a physical component (Dispersive Electrode), not a new AI algorithm requiring standalone performance evaluation. The software functionality (SMART Guide) is part of the established predicate device.

7. The Type of Ground Truth Used

• For the non-clinical tests conducted on the modified device, the "ground truth" would be engineering specifications, regulatory standards (like FDA recognized standards), and the established performance characteristics of the predicate device. The goal was to demonstrate that modifications did not compromise these established criteria.

8. The Sample Size for the Training Set

• Not applicable. Training sets are relevant for AI/ML model development. This document is about a physical device modification.

9. How the Ground Truth for the Training Set Was Established

• Not applicable. (See #8)

In summary: The provided FDA 510(k) letter pertains to a minor modification of an already cleared medical device (Sonata® Transcervical Fibroid Ablation System 2.2). The "study" described is a series of non-clinical verification and validation tests (biocompatibility, mechanical, electrical safety, etc.) on the modified components to ensure the device remains as safe and effective as its predicate. It does not involve a new clinical trial with human subjects or the evaluation of an AI/ML algorithm's performance, which would necessitate the detailed information requested in your questions related to ground truth, expert adjudication, or MRMC studies.

Ask a specific question about this device

The Sonata® Transcervical Fibroid Ablation System 2.2 is intrauterine imaging and transcervical treatment of symptomatic uterine fibroids, including those associated with heavy menstrual bleeding.

The Sonata System 2.2 provides radiofrequency (RF) ablation of uterine fibroids using a transcervical approach that is uterine sparing without incisions or material uterine distension. The system enables a clinician to deliver radiofrequency energy to fibroid tissue resulting in thermal fixation and coagulative necrosis of the tissue.

The system combines two technologies - ultrasound for visualization, and radiofrequency energy for ablative therapy - in a single integrated handpiece.

The Sonata System is comprised of medical equipment, software, and various single-use and reusable instruments. The change associated with this submission regards a software update to enable smaller ablations and other minor enhancements.

A single-use Radiofrequency Ablation (RFA) Handpiece attaches to a reusable Intrauterine Ultrasound (IUUS) Probe to provide sonography-guided RF ablation. Once connected, the combination is referred to as the "Treatment Device". The RFA Handpiece connects to the Sonata RF Generator and contains the Needle Electrodes that deliver radiofrequency energy to the target tissue. The IUUS Probe connects to the SMART Tablet and provides diagnostic ultrasound imaging and guidance. Ultrasound guidance is used to localize the fibroids from within the uterine cavity, guide placement of the RFA Handpiece Needle Electrodes into a target fibroid and ensure safety with respect to the serosa. When the Needle Electrodes are anchored within tissue, the physician is able to pivot the IUUS Probe transducer around the Needle Electrodes in order to confirm safety of the uterine serosa through multiple ultrasound planes.

The Sonata System allows for treatment planning through the use of a graphical interface and automated control of RF energy delivery.

Sonata Graphical Guidance Software (GGS) includes the SMART Guide and integrates treatment planning, targeting, and ablation of fibroids. The SMART Guide displays a real-time graphic overlay on the live ultrasound image for targeting and deployment of radiofrequency ablation.

Two main elements of the SMART Guide are the Ablation Zone and the Thermal Safety Border.

• . Ablation Zone (red inner ellipse) – a two-dimensional representation of the outer boundary of the average region of tissue ablation for the selected ablation size
• . Thermal Safety Border (green outer ellipse) - the distance at which tissue outside of the Ablation Zone is safe from the potential of thermal damage.

The provided FDA 510(k) summary for the Gynesonics Sonata Transcervical Fibroid Ablation System 2.2 explicitly states that "No additional clinical study data was needed to support substantial equivalence to the predicate." This means that the submission does not include a new clinical study to prove the device meets acceptance criteria.

Instead, the submission relies on:

• Identical Indications for Use: The modified device has the exact same indications as its predicate.
• Identical Technological Characteristics: The design, material, principle of operation, and energy source are the same as the predicate device.
• Software Modification: The only change is a software update to enable smaller ablations and minor enhancements.
• Non-Clinical Testing: Bench testing (ablation dimensions, treatment duration variations, volumetric ablation registration, dispersive electrode thermal performance), Finite Element Method (FEM) Computational Modeling, and software verification and validation were performed.

Therefore, I cannot provide the requested information regarding acceptance criteria and the study proving the device meets them, as the document states that a new clinical study was not conducted for this specific 510(k) submission. The FDA cleared this device based on its substantial equivalence to a previously cleared predicate device, supported by non-clinical testing of the software changes.

To directly answer your specific points based on the provided document:

1. A table of acceptance criteria and the reported device performance: This information is not provided in the document. The document states that "In all cases, the verification and validation testing met acceptance criteria," but it does not detail those criteria or the specific reported performance metrics.
2. Sample sized used for the test set and the data provenance: Not applicable, as no new clinical study (test set) was conducted. Non-clinical testing data provenance is not specified beyond "Gynesonics has applied their design control procedures."
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts: Not applicable.
4. Adjudication method for the test set: Not applicable.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance: Not applicable. This device is not an AI-assisted diagnostic tool, but an ablation system.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done: Not applicable. The software modifications are for controlling the ablation system directly, not for standalone diagnostic performance.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.): For non-clinical testing, ground truth would likely be established through engineering specifications, physical measurements from bench tests, and computational model outputs.
8. The sample size for the training set: Not applicable, as no new clinical study was conducted. Details about software training data (if any for the updates) are not provided in this regulatory summary.
9. How the ground truth for the training set was established: Not applicable.

Ask a specific question about this device

The Sonata Transcervical Fibroid Ablation System is intrauterine intrauterine imaging and transcervical treatment of symptomatic uterine fibroids, including those associated with heavy menstrual bleeding.

The Sonata System 2.2 provides radiofrequency (RF) ablation of uterine fibroids using a transcervical approach that is uterine sparing without incisions or material uterine distension. The system enables a clinician to deliver radiofrequency energy to fibroid tissue resulting in thermal fixation and coagulative necrosis of the tissue. The system combines two technologies - ultrasound for visualization, and radiofrequency energy for ablative therapy - in a single integrated handpiece. The Sonata System is comprised of medical equipment, software, and various single-use and reusable instruments. A single-use Radiofrequency Ablation (RFA) Handpiece attaches to a reusable Intrauterine Ultrasound (IUUS) Probe to provide sonography-guided RF ablation. Once connected, the combination is referred to as the "Treatment Device". The RFA Handpiece connects to the Sonata RF Generator and contains the Needle Electrodes that deliver radiofrequency energy to the target tissue. The IUUS Probe connects to the SMART Tablet and provides diagnostic ultrasound imaging and guidance. Ultrasound guidance is used to localize the fibroids from within the uterine cavity, guide placement of the RFA Handpiece Needle Electrodes into a target fibroid and ensure safety with respect to the serosa. When the Needle Electrodes are anchored within tissue, the physician is able to pivot the IUUS Probe transducer around the Needle Electrodes in order to confirm safety of the uterine serosa through multiple ultrasound planes. The Sonata System allows for treatment planning through the use of a graphical interface and automated control of RF energy delivery. Sonata Graphical Guidance Software (GGS) includes the SMART Guide and integrates treatment planning, targeting, and ablation of fibroids. The SMART Guide displays a real-time graphic overlay on the live ultrasound image for targeting and deployment of radiofrequency ablation. Two main elements of the SMART Guide are the Ablation Zone and the Thermal Safety Border. Ablation Zone (red inner ellipse) a two-dimensional representation of the outer boundary of the average region of tissue ablation for the selected ablation size. Thermal Safety Border (green outer ellipse) - the distance at which tissue outside of the Ablation Zone is safe from the potential of thermal damage. The change associated with this submission is an update to the Sonata Intrauterine Ultrasound (IUUS) Probe Instructions for Use to include an additional sterilization option.

The provided document is a 510(k) summary for the Sonata Transcervical Fibroid Ablation System 2.2. The purpose of this submission is to introduce an additional sterilization option for the Sonata Intrauterine Ultrasound (IUUS) Probe. As such, the study described focuses on ensuring the device meets acceptance criteria related to this change, primarily sterilization validation and device compatibility.

Here's the breakdown of the information requested:

1. Table of Acceptance Criteria and Reported Device Performance

2. Sample Size Used for the Test Set and Data Provenance

The document does not explicitly state the sample size for the test set used in the sterilization validation, biocompatibility, product life, basic safety, essential performance, or usability testing. These studies are typically non-clinical laboratory tests performed on a defined number of device units. The data provenance is not specified, but these tests would be conducted internally or by contract labs following established protocols. Given the nature of a 510(k) for a sterilization change, patient data (retrospective or prospective) is not directly applicable to proving the acceptance criteria for this specific modification.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

This type of information is not applicable to the non-clinical validation studies described in this 510(k) summary. "Experts" in this context would be laboratory personnel, engineers, and microbiologists trained in sterilization validation and device testing, but their role is to perform tests and interpret results against established standards, not to establish a "ground truth" in the way a clinical expert panel would for disease detection.

4. Adjudication Method for the Test Set

Not applicable. Adjudication is typically used in clinical studies when there are differing interpretations of clinical data or outcomes. For non-clinical validation of sterilization and device compatibility, the results are objectively measured against predefined acceptance criteria.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, If so, What Was the Effect Size of How Much Human Readers Improve with AI vs Without AI Assistance

Not applicable. The Sonata Transcervical Fibroid Ablation System is a medical device for treatment, not an AI-assisted diagnostic tool for human readers. The change described in this 510(k) focuses on sterilization validation, not clinical efficacy or diagnostic accuracy.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

Not applicable. The Sonata System is a physical medical device that combines ultrasound for visualization and radiofrequency energy for therapy; it is not a standalone algorithm.

7. The Type of Ground Truth Used

For the specific acceptance criteria validated in this 510(k) (sterilization, biocompatibility, etc.), the "ground truth" is established by:

• Sterilization: Regulatory standards and established scientific methods (e.g., AAMI standards for sterilization, sterility testing) that define what constitutes a sterile device (e.g., Sterility Assurance Level of 10^-6).
• Biocompatibility: ISO 10993 series of standards and other recognized guidelines for biological evaluation of medical devices.
• Product Life, Safety, Essential Performance, Usability: Device specifications, design requirements, and recognized industry standards.

8. The Sample Size for the Training Set

Not applicable. There is no "training set" in the context of an AI/machine learning algorithm for this type of medical device submission. The testing involves physical units of the device.

9. How the Ground Truth for the Training Set Was Established

Not applicable, as there is no training set for an AI/machine learning algorithm.

Ask a specific question about this device

The Sonata® Transcervical Fibroid Ablation System 2.2 is intended for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids, including those associated with heavy menstrual bleeding.

The Sonata System 2.2 provides radiofrequency (RF) ablation of uterine fibroids using a transcervical approach that is uterine sparing without incisions or material uterine distension. The system enables a clinician to deliver radiofrequency energy to fibroid tissue resulting in thermal fixation and coagulative necrosis of the tissue. The system combines two technologies - ultrasound for visualization, and radiofrequency energy for ablative therapy - in a single integrated handpiece. The Sonata System is comprised of medical equipment, software, and various single-use and reusable instruments. A single-use Radiofrequency Ablation (RFA) Handpiece attaches to a reusable Intrauterine Ultrasound (IUUS) Probe to provide sonography-guided RF ablation. Once connected, the combination is referred to as the "Treatment Device". The RFA Handpiece connects to the Sonata RF Generator and contains the Needle Electrodes that deliver radiofrequency energy to the target tissue. The IUUS Probe connects to the SMART Tablet and provides diagnostic ultrasound imaging and guidance. Ultrasound guidance is used to localize the fibroids from within the uterine cavity, guide placement of the RFA Handpiece Needle Electrodes into a target fibroid and ensure safety with respect to the serosa. When the Needle Electrodes are anchored within tissue, the physician is able to pivot the IUUS Probe transducer around the Needle Electrodes in order to confirm safety of the uterine serosa through multiple ultrasound planes. The Sonata System allows for treatment planning through the use of a graphical interface and automated control of RF energy delivery. Sonata Graphical Guidance Software (GGS) includes the SMART Guide and integrates treatment planning, targeting, and ablation of fibroids. The SMART Guide displays a real-time graphic overlay on the live ultrasound image for targeting and deployment of radiofrequency ablation.

The provided document is a 510(k) summary for the Sonata® Transcervical Fibroid Ablation System 2.2. It describes modifications made to an already cleared device and demonstrates substantial equivalence to its predicate. The critical point here is that this submission is for modifications to a previously cleared device, and thus, it largely leverages the safety and effectiveness data of the predicate device (K211535). The performance testing done for this specific submission focuses on verifying the impact of the changes.

Here's a breakdown of the requested information based on the provided text:

1. A table of acceptance criteria and the reported device performance

For this specific 510(k) submission (K222304), the performance testing was focused on the modifications to the device (new sterilization instructions for the IUUS Probe and the addition of the IUUS Probe Connector Protector). The document states:

"In all cases, the verification and validation testing met the acceptance criteria."

Therefore, the table will reflect the verification of the changes rather than comprehensive performance data of the entire system (as that was covered in the predicate device's clearance).

2. Sample sizes used for the test set and the data provenance

• For the modifications assessed in K222304 (sterilization and connector protector):

  • Sample Size: Not explicitly stated for each specific test (e.g., how many IUUS probes were tested for use life or biocompatibility with the new sterilization methods). However, the document indicates that "verification and validation testing met the acceptance criteria" for these changes.
  • Data Provenance: Not specified as a country of origin. This refers to bench testing and design control activities rather than human subject data. The validation was conducted by Gynesonics, Inc. as part of their design control procedures.
  • Retrospective/Prospective: These are likely prospective bench tests performed specifically for this submission.

• For the underlying clinical safety and effectiveness of the Sonata System (relied upon from predicate K211535):

  • Sample Size: 147 treated patients (n=147).
  • Data Provenance: The study (IDE G140114, NCT NCT02228174) included 22 centers with treated patients. The specific countries are not mentioned in this summary but are typically part of a full clinical study report.
  • Retrospective/Prospective: This was a single-arm cohort study, effectively prospective, where each subject served as their own control for assessing treatment outcomes.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

• For the modifications assessed in K222304: This refers to bench testing and design verification/validation. Ground truth would be defined by engineering specifications, recognized standards (e.g., ISO, IEC), and established test protocols. The document does not describe the involvement of external experts for establishing ground truth for these specific non-clinical tests, and it's not typically required for this type of verification.
• For the underlying clinical safety and effectiveness of the Sonata System (relied upon from predicate K211535): The document does not specify the number or qualifications of experts used to establish ground truth for the clinical outcomes. In clinical trials for this type of device, ground truth for fibroid diagnosis and treatment effect would typically be established by the treating physicians (e.g., gynecologists) and potentially independent assessment committees based on imaging (ultrasound, MRI) and patient-reported outcomes.

4. Adjudication method for the test set

• For the modifications assessed in K222304: Adjudication methods are not described for these bench tests. Compliance is determined against pre-defined engineering specifications and standard requirements.
• For the underlying clinical safety and effectiveness of the Sonata System (relied upon from predicate K211535): The document does not specify an adjudication method for the clinical trial endpoints. Clinical trials often employ independent data monitoring committees or clinical events committees for adjudication, but this detail is not present in the 510(k) summary.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

• Not Applicable. The Sonata System 2.2 is a medical device for fibroid ablation, not an AI-powered diagnostic system that relies on human readers interpreting images. While it uses "Sonata Graphical Guidance Software (GGS)" including a "SMART Guide" with "graphical overlay on the live ultrasound image for targeting and deployment," this is an integrated guidance system for the physician performing the procedure, not a standalone AI diagnostic tool requiring MRMC studies to assess reader improvement. The "SMART Guide" provides real-time visual assistance during the procedure.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

• Not Applicable. The Sonata System is not a standalone algorithm. It is a physical medical device (ablator) with integrated ultrasound imaging and software guidance, requiring direct human operation (human-in-the-loop) during the transcervical fibroid ablation procedure. The "SMART Guide" is an integral part of the user interface provided to the clinician.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)

• For the modifications assessed in K222304: The ground truth for these specific changes involves adherence to engineering specifications, validated sterilization protocols, biocompatibility standards, and functional performance criteria in bench testing.
• For the underlying clinical safety and effectiveness of the Sonata System (relied upon from predicate K211535): The clinical trial (IDE G140114) would have relied on a combination of:
  • Clinical outcomes data: Patient symptoms (e.g., heavy menstrual bleeding), quality of life.
  • Imaging: For fibroid identification, sizing, and assessment of treatment effect (e.g., volume reduction of ablated fibroids).
  • Safety data: Adverse event reporting.

8. The sample size for the training set

• Not Applicable. This document describes a medical device with integrated software guidance, not a machine learning or AI model that requires a distinct training set in the typical sense. The software (Sonata System Software v2.1.2) is likely developed through traditional software engineering processes, not by training on a large dataset of patient images or outcomes.

9. How the ground truth for the training set was established

• Not Applicable. As this is not an AI/ML system requiring a training set in the typical sense, there is no discussion of how ground truth for a training set was established. The software's functionality and guidance (the "SMART Guide") are based on established medical principles of ultrasound imaging and radiofrequency ablation, not derived from a trained dataset.

Ask a specific question about this device

The Sonata® Transcervical Fibroid Ablation System 2.2 is intended for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids, including those associated with heavy menstrual bleeding.

The Sonata System 2.2 provides radiofrequency (RF) ablation of uterine fibroids using a transcervical approach that is uterine sparing without incisions or material uterine distension. The system enables a clinician to deliver radiofrequency energy to fibroid tissue resulting in thermal fixation and coagulative necrosis of the tissue. The system combines two technologies - ultrasound for visualization, and radiofrequency energy for ablative therapy - in a single integrated handpiece. The Sonata System is comprised of medical equipment, software, and various single-use and reusable instruments. A single-use Radiofrequency Ablation (RFA) Handpiece attaches to a reusable Intrauterine Ultrasound (IUUS) Probe to provide sonography-guided RF ablation. Once connected, the combination is referred to as the "Treatment Device". The RFA Handpiece connects to the Sonata RF Generator and contains the Needle Electrodes that deliver radiofrequency energy to the target tissue. The IUUS Probe connects to the SMART Tablet and provides diagnostic ultrasound imaging and guidance. Ultrasound guidance is used to localize the fibroids from within the uterine cavity, guide placement of the RFA Handpiece Needle Electrodes into a target fibroid and ensure safety with respect to the serosa. The Sonata System allows for treatment planning through the use of a graphical interface and automated control of RF energy delivery. Sonata Graphical Guidance Software (GGS) includes the SMART Guide and integrates treatment planning, targeting, and ablation of fibroids. The SMART Guide displays a real-time graphic overlay on the live ultrasound image for targeting and deployment of radiofrequency ablation.

The provided document is a 510(k) summary for the Sonata® Transcervical Fibroid Ablation System 2.2. It describes changes made to the device compared to its predicate (Sonata System 2.1) and summarizes the testing conducted to demonstrate substantial equivalence.

However, the document does not contain the detailed information requested regarding acceptance criteria for a study proving the device meets acceptance criteria. Instead, it outlines the company's internal design control procedures, risk analysis, and verification/validation activities for the modifications to the device. It also references prior clinical data from the predicate device and states that no additional clinical data was needed for the 2.2 version.

Specifically, the document does not provide:

1. A table of acceptance criteria and reported device performance from a study proving device meets acceptance criteria. It lists "Performance testing - System level (bench)" and "Performance testing - Ablation" but describes the types of tests, not the specific acceptance criteria or quantitative results.
2. Sample sizes used for a test set in the context of proving performance against acceptance criteria.
3. Number of experts, their qualifications, or adjudication methods for establishing ground truth for a test set. This type of information is usually relevant for AI/ML device evaluations, which this device is not.
4. Details on an MRMC comparative effectiveness study or standalone performance. This device is not an AI/ML device subject to these types of studies.
5. Type of ground truth (e.g., pathology, outcomes data) for a test set.
6. Sample size for a training set.
7. How ground truth for a training set was established.

What the document does provide, relative to your questions:

• Acceptance Criteria & Performance (General):

  • The document states that "The test methods and acceptance criteria used established methods consisting of FDA recognized standards and/or the same methods and criteria as were used in the predicate device submission; thus, meeting the FDA's requirement for a Special 510(k). In all cases, the verification and validation testing met the acceptance criteria."
  • It lists general safety and performance standards met (e.g., Electrical Safety & EMC: ANSI/AAMI ES60601-1, IEC 60601-1-2, etc.).
  • Acoustic Output: Specific values are given for B Mode: ISPTA ≤ 720 mW/cm² (Value: 162 mW/cm²) and MI ≤ 1.9 (Value: 1.7). These are presented as performance measurements.

• Study Proving Device Meets Acceptance Criteria:

  • The document focuses on demonstrating that the changes to the Sonata System 2.2 do not raise new questions of safety and effectiveness, relying heavily on the predicate device's existing data.
  • It mentions "verification and validation testing met the acceptance criteria" for the changes, but doesn't provide a specific study report for this, instead summarizing design control activities in Table 5. These are generally internal engineering tests.
  • For clinical data: "No additional clinical study data was needed to validate the Sonata System 2.2." It explicitly states that "Sonata System 2.2 continues to rely on the clinical trial study as Sonata System 2.1."

• Clinical Trial for Predicate Device (G140114, NCT02228174):

  • Sample Size: n = 147 subjects.
  • Data Provenance: 22 centers with treated patients. (Country of origin not specified, but typically US-based for FDA filings). The trial design was a "Single-arm cohort study with each subject serving as her own control."
  • Ground Truth: For the clinical trial, the "ground truth" would be related to clinical outcomes (safety and effectiveness, e.g., reduction in heavy menstrual bleeding, fibroid volume reduction, adverse events) as assessed by clinicians or objective measurements, not image-based expert consensus. The document does not detail how these clinical outcomes were specifically established, but this is typical for clinical trials where physician assessment and quantitative measurements are used.
  • Retrospective/Prospective: Clinical trials are typically prospective.

• AI/ML Specific Questions (not applicable to this device, as it's not an AI/ML diagnostic tool):

  • Number of experts, qualifications, and adjudication methods for ground truth (Q3, Q4) are not relevant as this is not an AI/ML device.
  • MRMC comparative effectiveness study (Q5) is not relevant.
  • Standalone performance (Q6) is not relevant in the context of AI/ML algorithms. The device's performance is as an integrated system, not a standalone algorithm.
  • Training set information (Q8, Q9) is not relevant as there's no mention of a machine learning algorithm being trained.

Summary Table based on provided text (limited details):

Study Proving Device Meets Acceptance Criteria (Clinical Trial of Predicate):

• Sample size: n = 147 subjects.
• Data Provenance: 22 centers. (Retrospective/Prospective: Typically Prospective for clinical trials). Country not explicitly stated, but for FDA submissions, often includes US sites.
• Number of experts used to establish ground truth & qualifications: Not applicable for a device that is not an AI/ML diagnostic. The clinical trial would establish efficacy and safety through patient outcomes and physician assessments.
• Adjudication method for the test set: Not applicable for device performance against a test set in the AI/ML sense. Data in the clinical trial would be collected and analyzed using standard clinical trial methodologies.
• MRMC comparative effectiveness study: No.
• Standalone performance: Not applicable in the AI/ML context. This is an integrated surgical system.
• Type of ground truth used: Clinical outcomes data (e.g., reduction in heavy menstrual bleeding, fibroid volume, adverse events) from a single-arm cohort study where each subject served as her own control.
• Sample size for training set: Not applicable (not an AI/ML device).
• How ground truth for training set was established: Not applicable.

Ask a specific question about this device